Iranian Red Crescent Medical Journal

Published by: Kowsar

Construction of Recombinant Bacmid Containing M2e-Ctxb and Producing the Fusion Protein in Insect Cell Lines

Nima Mirzaei 1 , * , Talat Mokhtari Azad 2 , Rakhshandeh Nategh 2 , Hoorieh Soleimanjahi 3 and Nour Amirmozafari 4
Authors Information
1 Department of Biology, Science and Research branch, Islamic Azad University, Tehran, IR Iran
2 Department of Virology, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Virology, Tarbiat Modares University, Tehran, IR Iran
4 Department of Microbiology, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: February 7, 2014, 16 (2); e13176
  • Published Online: February 7, 2014
  • Article Type: Research Article
  • Received: June 30, 2013
  • Revised: July 27, 2013
  • Accepted: November 18, 2013
  • DOI: 10.5812/ircmj.13176

To Cite: Mirzaei N, Mokhtari Azad T, Nategh R, Soleimanjahi H, Amirmozafari N. Construction of Recombinant Bacmid Containing M2e-Ctxb and Producing the Fusion Protein in Insect Cell Lines, Iran Red Crescent Med J. 2014 ; 16(2):e13176. doi: 10.5812/ircmj.13176.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. WHO Position Paper on Influenz a Vaccines: Selected references. 2005;
  • 2. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006; 295(8): 891-4[DOI][PubMed]
  • 3. Hehme N, Colegate T, Palache B, Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine. 2008; 26 Suppl 4-6[PubMed]
  • 4. Global pandemic influenza action plan to increase vaccine supply, Vaccines and Biologicals Epidemic and Pandemic Alert and Response. 2006;
  • 5. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am. 2004; 18(1): 141-55[DOI][PubMed]
  • 6. Kuiken T, Fouchier R, Rimmelzwaan G, Osterhaus A. Emerging viral infections in a rapidly changing world. Curr Opin Biotechnol. 2003; 14(6): 641-6[PubMed]
  • 7. Nicholson KG, Webster RG, Hay AJ. Genetic Reassortment of Human Influenza Viruses in Nature, Textbook of Influenza. 1998;
  • 8. International Federation of Pharmaceutical Manufacturers & Associations. Influenza vaccine supply international task force. Technical briefing for WHO intergovernmental meeting on sharing of influenza viruses and access to vaccines and other benefits. 2007;
  • 9. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005; 18(1): 244-51[DOI][PubMed]
  • 10. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine. 2008; 26(49): 6232-6[DOI][PubMed]
  • 11. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008; 26(27-28): 3395-403[DOI][PubMed]
  • 12. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol. 1994; 68(3): 1551-63[PubMed]
  • 13. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008; 26(2): 201-14[DOI][PubMed]
  • 14. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem. 2006; 281(14): 8997-9000
  • 15. Razavi NH, Soleimanjahi H, Fotouhi F, Ghaemi A, Fazeli M. Construction of the Chimeric HSP70-E7 Vector and Evaluation of its Protein Production. Iran J Virol. 2009; 3(3): 29-34
  • 16. Areas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun. 2004; 321(1): 192-6[DOI][PubMed]
  • 17. Müller D, Bayer K, Mattanovich D. Potentials and limitations of prokaryotic and eukaryotic expression systems for recombinant protein production--a comparative view. Microb Cell Fact. 2006; 5: 61
  • 18. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res. 2006; 68: 193-253[DOI][PubMed]
  • 19. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 1995; 214(1): 50-8[DOI][PubMed]
  • 20. Airenne KJ, Peltomaa E, Hytonen VP, Laitinen OH, Yla-Herttuala S. Improved generation of recombinant baculovirus genomes in Escherichia coli. Nucleic Acids Res. 2003; 31(17)[PubMed]
  • 21. Gouya MM, Nabavi M, Soroush M, Haghdoust AA, Ghalehee S, Hemmati P, et al. Mortality from Pandemic Influenza A (H1N1) in Iran. Iran Red Crescent Med J. 2011; 13(10): 698-701[PubMed]
  • 22. Lankarani KB, Sabayan B. H1N1 influenza pandemics 2009: from myths to facts. Iran Red Cres Med J. 2010; 12(4): 354-7
  • 23. Ebrahimi SM, Aghaiypour K, Nili H. Sequence analysis of M2 gene of avian influenza virus strain (A/Chicken/Iran/101/98 (H9N2)) as an oil vaccine seed. Iran J Biotech. 2008; 6(4)
  • 24. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes. 2011; 42(1): 1-8[DOI][PubMed]
  • 25. Andersson AM, Hakansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One. 2012; 7(10)[DOI][PubMed]
  • 26. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, et al. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One. 2012; 7(9)[DOI][PubMed]
  • 27. Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun. 2005; 73(9): 5654-65[DOI][PubMed]
  • 28. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8(4): 499-508[DOI][PubMed]
  • 29. Ebrahimi SM, Tebianian M, Mirjalili A, Paykari H, Varshovi HR, Toghyani H, et al. Fusion and sequence analysis of the influenza A (H9N2) virus M2e and C-terminal fragment of Mycobacterium tuberculosis HSP70 (H37Rv). Arch Razi. 2009; 64(2): 71-6
  • 30. Kim EH, Lee JH, Pascua PN, Song MS, Baek YH, Kwon HI, et al. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J. 2013; 10: 104[DOI][PubMed]
  • 31. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83: 1851-9[PubMed]
  • 32. Smith GE, Summers MD, Fraser MJ. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol. 1983; 3(12): 2156-65[PubMed]
  • 33. Belzhelarskaia SN. [A baculovirus expression system for insect cells]. Mol Biol (Mosk). 2002; 36(3): 371-85[PubMed]
  • 34. Kidd IM, Emery VC. The use of baculoviruses as expression vectors. Applied Biochem Biotech. 1993; 42(2-3): 137-59
  • 35. Li SF, Wang HL, Hu ZH, Deng F. Genetic modification of baculovirus expression vectors. Virol Sin. 2012; 27(2): 71-82[DOI][PubMed]
  • 36. Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012; 7(12)[DOI][PubMed]
  • 37. Rezaei F, Mirshafiey A, Shahmahmoodi S, Shoja Z, Ghavami N, Mokhtari-Azad T. Influenza Virus-like Particle Containing Two Different Subtypes of Hemagglutinin Confers Protection in Mice Against Lethal Challenge With A/PR8 (H1N1) and A/HK (H3N2) Viruses. Iran Red Crescent Med J. 2013; 15(1): 75-82[DOI][PubMed]
  • 38. Safdar A, Cox MM. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs. 2007; 16(7): 927-34[DOI][PubMed]
  • 39. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 1995; 13(15): 1399-402[PubMed]
  • 40. Salmani Z, Behzadian F, Fotouhi Chahooki F, Fallah J. Construction of a Recombinant Bacmid DNA to Express Influenza Virus Matrix Protein1 (M1) in Insect Cell Line. Iran J Virol. 2010; 4(3): 23-8
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments